Reproductive toxicity testing of therapeutic biotechnology agents

Teratology

Volumn 53, Issue 3, 1996, Pages 185-195

  Henck, Judith W ^a   Hilbish, Kim G ^b   Serabian, Mercedes A ^c   Cavagnaro, Joy A ^c   Hendrickx, Andrew G ^d   Agnish, Narsingh D ^e   Kung, Ada H C ^f   Mordenti, Joyce ^g  

^a PFIZER INC   (United States)

^b Miles Inc   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOFFMANN LA ROCHE INC   (United States)

^f Skyline Technol Consult Grp Inc   (United States)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL TERATOGEN; DORNASE ALFA; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOTECHNOLOGY; CONFERENCE PAPER; DRUG SAFETY; FEMALE; FETUS; HUMAN; METHODOLOGY; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; TERATOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOTECHNOLOGY; CHIMERA; DRUG AND NARCOTIC CONTROL; FEMALE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PHARMACOKINETICS; PREGNANCY; PRIMATES; RATS; REPRODUCTION; RESEARCH DESIGN; TOXICITY TESTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0029894596     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9926(199603)53:3<185::AID-TERA6>3.0.CO;2-3     Document Type: Conference Paper

References (33)

1. Allansmith, M., B.H. McClellan, M. Butterworth, and J.R. Maloney (1968) The development of immunoglobulin levels in man. J. Pediatr., 72:276-290.
2. Boscato, L.M., and M.C. Stuart (1988) Heterophilic antibodies: A problem for all immunoassays. Clin. Chem., 34:27-33.
3. Bryson, H.M., and E.M. Sorkin (1994) Dornase alfa: A review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs, 48:894-906.
4. Byrn, R.A., I. Sekigawa, S. Chamow, J.S. Johnson, T.J. Gregory, D.J. Capon, and J.E. Groopman (1989) Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J. Virol., 63:4370-4375.
5. Byrn, R.A., J. Mordenti, C. Lucas, D. Smith, S.A. Maraters, J.S. Johnson, P. Cossum, S.M. Chamow, P.M. Wurm, T. Gregory, J.E. Groopman, and D.J. Capon (1990) Biological properties of CD4 immunoadhesin. Nature, 344:667-670.
6. Capon, D., S. Chamow, J. Mordenti, S.A. Marsters, T. Gregory, H. Mitsuya, R.A. Bum, C. Lucas, F.M. Wurm, J.E. Groopman, S. Broder, and D.H. Smith (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature, 337:525-531.
7. Cavagnaro, J.A. (1993) Preclinical safety assessment of biological products. In: Biologies Development: A Regulatory Overview. M. Matthieu, ed. Paraxel International Corp., Waltham, Massachusetts, pp. 23-40.
8. Clarke, D.O., B.A. Elswick, F. Welsch, and R.B. Conolly (1993) Pharmacokinetics of 2-methoxyethanol and 2-methoxyacetic acid in the pregnant mouse: A physiologically based mathematical model. Toxicol. Appl. Pharmacol., 121-239-252.
9. Dean, J.H., J.B. Cornacoff, G.J. Rosenthal, and M.I. Luster (1989) Immune system: Evaluation of injury. In: Principles and Methods of Toxicology, Second Edition. A.W. Hayes, ed. Raven Press, New York, pp. 741-760.
10. Green, J.D. (1994) Pharmacological-toxicological expert report on recombinant human deoxyribonuclease I (rhDNase; Pulmozyme™). Hum. Exp. Toxicol., 13:1-41.
11. Hendrickx, A.G., and M.C. Cukierski (1987) Reproductive and developmental toxicology in nonhuman primates. Prog. Clin. Biol. Res., 235:73-88.
12. Hendrickx, A.G., P.E. Binkerd, and J.M. Rowland (1983) Developmental toxicity and nonhuman primates: Interspecies comparisons. In: Issues and Reviews in Teratology. H. Kalter, ed.: Plenum Publishing Corporation, New York, Vol. 1, pp. 149-180.
13. Hobson, W.C., and G.B. Fuller (1987) Species selection for safety evaluation of biotechnology products. Prog. Clin. Biol. Res., 235:55-71.
14. International Conference on Harmonisation (ICH) (1994) Guideline on detection of toxicity to reproduction for medicinal products. Fed. Reg., 59:48746-48752.
15. Kohn, F.R., R.J. Bauer, and A.H.C. Kung. Anti-CD5 monoclonal antibody treatment in the rat: Relationship between T-cell binding, depletion, plasma kinetics and efficacy in experimental arthritis. In preparation.
16. Krauer, B., F. Krauer, and F.E. Hytten (1980) Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol. Ther., 10:301-328.
17. Kung, A.H.C., K.N. Kong, K.A. Achilles, V.L. Mohler, and M.L. White (1994) A continuous infusion animal model for the immunoconjugate, XomaZyme-CD5 Plus, in the rat. J. Am. Coll. Toxicol., 13:64-75.
18. Kung, A.H.C., J. Cavagnaro, A. Makin, M.A. White, and K.M. Kong (1995) Toxicologic evaluations of an immunotoxin, H6S-RTA. Fundam. Appl. Toxicol., 26:75-84.
19. Lee, K.B., Jr., and G.S. Burrill (1994) Biotech 95: Reform, Restructure, Renewal. The Industry Annual Report. Palo Alto, California: Ernst & Young LLP, pp. 22-23.
20. Maddon, P.J., A.G. Dalgleish, J.S. McDougal, P.R. Clapham, R.A. Weise, and R. Axel (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell, 47:333-348.
21. Manson, J.M., and L.D. Wise (1991). Teratogens. In: Casarett & Doull's Toxicology. M.O. Amdur, J. Doull, and C. Klaassen, eds. Pergamon Press, New York, pp. 226-254.
22. Mordenti, J., S.A. Chen, and B.L. Ferraiolo (1993) Pharmacokinetics of interferon-gamma. In: Therapeutics Proteins: Pharmacokinetica and Pharmacodynamics. A.H.C. Kung, R.A. Baughman, and J.W. Larrick, eds. W.H. Freeman and Company, New York, pp. 187-199.
23. O'Flaherty, E.J., W. Scott, C. Schreiner, and R. Beliles (1992) A physiologically based kinetic model of rat and mouse gestation: Disposition of a weak acid. Toxicol. Appl. Pharmacol., 112:245-256.
24. Olanoff, L., and J. Anderson (1980) Controlled release of tetracycline-III: A physiological pharmacokinetic model of the pregnant rat. J. Pharmacokinet. Biopharm., 8:599-620.
25. Pacifici, G.M., and R. Nottoli (1995) Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 28:235-269.
26. Rubin, S. (1993) Biotechnology and the pharmaceutical industry. Cancer Invest., 11:451-457.
27. Siegel, J.P., T. Gerrard, J.A. Cavagnaro, P. Keegan, R.P. Cohen, and K. Zoon (1995) Development of biological therapeutics for oncologic use. In: Biological Therapy of Cancer, Second Edition. V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, eds. J.B. Lippincott Co., Philadelphia, pp. 879-890.
28. Smith, D., R.A. Byrn, S. Marsters, T. Gregory, J.E. Groopman, and D.J. Capon (1987) Blocking of HIV-1 infectivity by soluble, secreted form of the CD4 antigen. Science, 235:1704-1707.
29. Stromberg, K., M.S. Chapekar, B.A. Goldman, W.A. Chambers, and J.A. Cavagnaro (1995) Regulatory concerns in the development of topical recombinant ophthalmic and cutaneous wound healing biologics. Wound Rep. Reg., 2.155-164.
30. Terrell, T.G., and J.D. Green (1993) Comparative pathology of recombinant murine interferon-gamma in mice and recombinant human interferon-gamma in cynomolgus monkeys. Int. Rev. Exp. Pathol., 34:73-101.
31. Trown, P.W., R.J. Wills, and J.J. Kamm (1986) The preclinical development of Roferon®-A. Cancer 57:1648-1656.
32. Ward, R.M. (1995) Pharmacological treatment of the fetus. Clinical pharmacokinetic considerations. Clin. Pharmacokinet. 25:343-350.
33. Weber, T.H., K. Kapyaho, and P. Tanner (1990) Endogenous interference in immunoassays in clinical chemistry: A review. Scand. J. Clin. Lab. Invest. [Suppl.], 50:77-82.